280 related articles for article (PubMed ID: 34014847)
1. Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition.
Raychaudhuri S; Cheema KS; Raychaudhuri SK; Raychaudhuri SP
Curr Opin Rheumatol; 2021 Jul; 33(4):348-355. PubMed ID: 34014847
[TBL] [Abstract][Full Text] [Related]
2. JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance.
Raychaudhuri SP; Shah RJ; Banerjee S; Raychaudhuri SK
Curr Rheumatol Rep; 2024 Jun; 26(6):204-213. PubMed ID: 38492148
[TBL] [Abstract][Full Text] [Related]
3. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
4. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
McInnes IB; Szekanecz Z; McGonagle D; Maksymowych WP; Pfeil A; Lippe R; Song IH; Lertratanakul A; Sornasse T; Biljan A; Deodhar A
Rheumatology (Oxford); 2022 May; 61(5):1783-1794. PubMed ID: 34668515
[TBL] [Abstract][Full Text] [Related]
5. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
[TBL] [Abstract][Full Text] [Related]
6. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
[TBL] [Abstract][Full Text] [Related]
7. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
O'Brien A; Hanlon MM; Marzaioli V; Wade SC; Flynn K; Fearon U; Veale DJ
Front Immunol; 2021; 12():672461. PubMed ID: 34248953
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase/signal transducer and activator of transcription pathways in spondyloarthritis.
Raychaudhuri SK; Raychaudhuri SP
Curr Opin Rheumatol; 2017 Jul; 29(4):311-316. PubMed ID: 28394822
[TBL] [Abstract][Full Text] [Related]
9. The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights.
Toussirot E
Pharmaceuticals (Basel); 2022 Feb; 15(3):. PubMed ID: 35337068
[TBL] [Abstract][Full Text] [Related]
10. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibitor: Introduction.
Raychaudhuri SP; Raychaudhuri SK
Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
[TBL] [Abstract][Full Text] [Related]
12. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I; Pikiewicz W; Kaminiów K
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease.
Huo R; Guo Q; Hu J; Li N; Gao R; Mi L; Zhang Z; Liu H; Guo Z; Zhao H; Zhang L; Xu K
Drug Des Devel Ther; 2022; 16():991-998. PubMed ID: 35400994
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibitors in autoimmune bullous diseases.
Huang D; Zhang Y; Kong L; Lu J; Shi Y
Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
[TBL] [Abstract][Full Text] [Related]
15. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibitors and autoimmune rheumatic diseases.
Benucci M; Bernardini P; Coccia C; De Luca R; Levani J; Economou A; Damiani A; Russo E; Amedei A; Guiducci S; Bartoloni E; Manfredi M; Grossi V; Infantino M; Perricone C
Autoimmun Rev; 2023 Apr; 22(4):103276. PubMed ID: 36649877
[TBL] [Abstract][Full Text] [Related]
17. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
[TBL] [Abstract][Full Text] [Related]
18. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
[TBL] [Abstract][Full Text] [Related]
19. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibition in the treatment of inflammatory rheumatic diseases.
Šenolt L
Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]